Alnylam Pharmaceuticals Phase III ILLUMINATE-A clinical trial of lumasiran has met the primary and secondary endpoints in patients suffering from primary hyperoxaluria type 1 (PH1).

Lumasiran is an investigational, subcutaneous gene silencing RNAi therapeutic that targets hydroxyacid oxidase 1 (HAO1), which is involved in the development of PH1.

The 30-patient ILLUMINATE-A trial compared a 3mg/kg monthly dose of lumasiran to placebo for three months at 16 sites across eight countries.

The primary endpoint was the percentage change in average 24-hour urinary oxalate excretion over three to six months compared to placebo.

Alnylam’s drug also demonstrated statistical significance for all tested secondary endpoints, including near-normal or normal urinary oxalate levels.

Lumasiran was generally well tolerated, with no serious or severe adverse events observed during the trial. The overall profile was generally consistent with that found in Phase I/II and open-label extension studies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Alnylam Pharmaceuticals R&D president Akshay Vaishnaw said: “The results from ILLUMINATE-A demonstrate that lumasiran can significantly reduce the hepatic production of oxalate, which we believe can thereby address the underlying pathophysiology of PH1.

“Further, we are encouraged by the safety and tolerability profile of lumasiran and believe this investigational medicine has the potential to have a meaningful clinical impact on patients living with PH1.”

Based on the Phase III ILLUMINATE-A data, the company intends to submit applications early next year seeking approval for lumasiran from the US and European regulatory authorities.

The drug holds orphan drug designation in the US and EU, along with breakthrough therapy designation in the US and priority medicines (PRIME) designation in the EU.

Alnylam is also assessing the drug in the Phase III ILLUMINATE-B and ILLUMINATE-C trials to treat PH1.